Teva Pharmaceutical Industries Limited Share Price TEL AVIV STOCK EXCHANGE
Equities
IL0006290147
Pharmaceuticals
Sales 2024 * | 15.95B 59.1B 1,256B | Sales 2025 * | 16.52B 61.2B 1,301B | Capitalization | 18.45B 68.35B 1,453B |
---|---|---|---|---|---|
Net income 2024 * | 820M 3.04B 64.57B | Net income 2025 * | 1.39B 5.14B 109B | EV / Sales 2024 * | 2.09 x |
Net Debt 2024 * | 14.93B 55.29B 1,175B | Net Debt 2025 * | 12.41B 45.97B 977B | EV / Sales 2025 * | 1.87 x |
P/E ratio 2024 * |
17.3
x | P/E ratio 2025 * |
12.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.71% |
Latest transcript on Teva Pharmaceutical Industries Limited
Managers | Title | Age | Since |
---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 55 | 31/12/22 |
Eli Kalif
DFI | Director of Finance/CFO | 51 | 21/12/19 |
Eric Hughes
CTO | Chief Tech/Sci/R&D Officer | - | 31/07/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerald Lieberman
BRD | Director/Board Member | 77 | 31/08/15 |
Janet Vergis
BRD | Director/Board Member | 59 | 08/06/20 |
Sol Barer
CHM | Chairman | 76 | 31/12/14 |
1st Jan change | Capi. | |
---|---|---|
+32.09% | 694B | |
+29.39% | 593B | |
-1.34% | 371B | |
+20.34% | 331B | |
+7.39% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.49% | 169B |